Literature DB >> 2939229

Effect of L-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors.

A Bezeaud, L Drouet, G Leverger, J H Griffin, M C Guillin.   

Abstract

Vitamin K-dependent proteins were measured sequentially by immunoassay in eight patients with acute lymphoblastic leukemia receiving L-asparaginase (1000 U/kg/day) for 10 days as induction therapy, in combination with vincristine or vindesine, daunorubicin, cyclophosphamide, and prednisone. The level of each protein was significantly decreased during L-asparaginase therapy, but both the time course of change and the severity of decrease differed among the proteins. The decrease in protein C, factor IX, and factor X was observed earlier than the decrease in protein S and factor II. In the first days of L-asparaginase therapy the protein C level was significantly lower than those of the other vitamin K-dependent proteins. The transient imbalance in the levels of plasma vitamin K-dependent proteins observed in the first days of treatment may contribute to the risk of thrombosis associated with L-asparaginase therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939229     DOI: 10.1016/s0022-3476(86)81044-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Effects of the antileukemic drug L-asparaginase on sex hormone-binding globulin: studies in vivo and in vitro.

Authors:  L Bartalena; E Martino; A Pacchiarotti; S Balzano; M Falcone; V Sica; P Biddau; A Pinchera
Journal:  J Endocrinol Invest       Date:  1989 Jul-Aug       Impact factor: 4.256

Review 2.  Approach to chemotherapy-associated thrombosis.

Authors:  Peter Oppelt; Anthony Betbadal; Lalitha Nayak
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

3.  Subacute leukoencephalopathy complicating acute lymphoblastic leukemia.

Authors:  F M Filloux; J J Townsend
Journal:  West J Med       Date:  1987-02

Review 4.  Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options.

Authors:  Nasrin Samji; Mihir D Bhatt; Ketan Kulkarni
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.569

Review 5.  Cancer Therapy-Associated Thrombosis.

Authors:  Steven P Grover; Yohei M Hisada; Raj S Kasthuri; Brandi N Reeves; Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-11       Impact factor: 8.311

6.  Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management.

Authors:  Marwa S Hamza; Shaker A Mousa
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.